A Study to Evaluate the Safety and Efficacy of A2B395
Phase 1/2
240
about 4.9 years
18+
10 sites in AZ, CA, FL +5
What this study is about
This trial is testing a treatment called A2B395, which is an allogeneic logic-gated CAR T cell product. The goal is to see if this treatment is safe and effective for people with solid tumors that express EGFR and have lost HLA-A*02 expression.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive A2B395
- 2.XT CDx with HLA-LOH assay
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level, Phase 2: The overall response rate (ORR) for patients
Secondary: Cytokine analysis
diagnostic
Oncology, Gastroenterology, Respiratory